{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2000"],"condition":["Colorectal Neoplasms"],"disease":["Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2171181"],"study_start_month":["2"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer","description":"Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic colorectal cancer.","dates":{"creation":"2000-02-15"},"accession":"2171181","cross_references":{"ClinicalTrials___gov":["NCT02198274"]}}